Introduction AL (amyloid light chain) amyloidosis is a result of clonal plasma cell disorder with an incidence of five to 13 persons per million per year. 1 It is the most common and most severe form of systemic amyloidosis. The monoclonal light chains form fibrils that deposit and accumulate in tissues such as the kidney, heart, gastrointestinal tract, liver or autonomic nervous system resulting in organ dysfunction and failure. 2 Without therapy the median survival is 10-14 months from diagnosis. 1, 3 Patients with predominantly cardiac involvement have lower median survivals at o5 months. 1, 3 The standard treatment for AL amyloidosis with cyclical oral melphalan and prednisone results in haematological remission in approximately 20-30% of patients, slows disease progression and increases the median survival from 13 to 17 months. [4] [5] [6] In a recently published study, oral melphalan combined with high-dose dexamethasone (MDex) produced better haematological (67%) and organ function (48%) responses indicating that this schedule may be superior to the former melphalan and prednisone. 7 Owing to new treatment options and better supportive care the outcome after conventional chemotherapy in AL amyloidosis has improved since 1990 with an increase in survival to 29 months. 8 However, high-dose melphalan and autologous stem cell transplantation (HDM-ASCT) has been considered an efficient therapeutic approach since promising treatment results were reported in the last 10 years. [9] [10] [11] The procedure appears to prolong survival if haematological remission of the plasma cell disease can be achieved, which is possible in up to 50% of patients but is associated with high mortality rates of 15-40%. [11] [12] [13] [14] Remarkably, the first prospective randomized study comparing HDM-ASCT with oral melphalan and dexamethasone did not demonstrate statistical difference in haematological response, organ function response or survival between the two treatment modalities in a multicentric setting. 15 On the other hand, a case control study showed a survival advantage for the HDM-ASCT patient group. 16 Therefore, it remains controversial at present, whether one of the two treatment approaches -oral conventional chemotherapy or HDM-ASCT -is superior. Only a few studies focus on long-term survival beyond 3 years from after HDM-ASCT. 14 We analysed treatment data in a series of patients from the Hammersmith Hospital, London, in whom the median survival now reaches 4 years.
Patients and methods

Patients
Between August/1996 and December/2001, we treated 19 patients with systemic AL amyloidosis by HDM-ASCT. All the patients were referred for a full assessment and evaluation of eligibility to undergo HDM-ASCT to the National Amyloidosis Centre, initially at the Hammersmith Hospital and later at the Royal Free Hospital, London. To estimate the extent of organ involvement, disease history, physical examination and the following investigations were performed: I 123 -labelled serum amyloid P (SAP) scintigraphy, 17 electrocardiogram (ECG), echocardiography (ECHO), chest X-ray, skeletal X-rays, abdominal ultrasound, standardised laboratory blood testing including liver and kidney function, 24 h urine collection with quantitation of total protein and light chain excretion, electrophoresis, immunoelectrophoresis and immunofixation of urine and serum, bone marrow aspiration, bone marrow biopsy and, if appropriate, organ biopsy for histological examination. 18 Some patients underwent functional evaluation of their autonomic nervous system. Cardiac, renal, liver or gastrointestinal involvement were confirmed by clinical diagnostic criteria described previously. 11, 13, 14 Neurological syndromes included symptoms or signs of peripheral sensory neuropathy, motor neuropathy or autonomic neuropathy associated with orthostatic hypotension. Organs with evidence of amyloid disease involvement on either SAP scan or echocardiography or organ biopsy or appropriate organ system examination (neuropathy assessment) were counted to establish the number of organs involved at diagnosis. Patients were considered eligible for HDM-ASCT if they met the following inclusion criteria: age between 18 and 65 years, performance status 0-2 according to World Health Organisation (WHO) criteria and ventricular ejection fraction 430%. Impaired renal function was not a reason for exclusion.
Stem cell collection and transplantation
Stem cells were collected from the peripheral blood using granulocyte colony-stimulating factor (G-CSF: Filgrastim, Amgen, UK or Lenograstim, Chugai Pharma, UK) at a dose of 10 mg/kg daily for 5 days or at a dose of 5 mg/kg daily with preceding cyclophosphamide or etoposide chemotherapy. A minimum of 2.0 Â 10 6 CD34 þ cells per kg body weight was required to proceed with transplant. Patients received intravenous HDM at a dose of 200 mg/m 2 or at modified doses in the presence of renal or cardiac dysfunction. Autologous stem cells were infused 48 h after the administration of HDM.
Treatment response and outcome evaluation
The primary outcome measure was survival. Patients were assessed for therapy-related toxicity, for haematological and clinical response at 3, 6 and 12 months after HDM-ASCT and annually thereafter. At each evaluation clinical examination and laboratory testing of serum and urine (24 h urine collection) were performed including electrophoresis, immunoelectrophoresis, immunofixation and serumfree light chain ratio assessment. Serum amyloid P scan was performed prior to ASCT and 12 months after ASCT.
Haematological and clinical response criteria
The definition of haematological response to transplant was adapted from that published for multiple myeloma. 19 Complete haematological response (CR) required the absence of persistent plasma cell disease in the bone marrow, that is, o5% of plasma cells without light chain restriction and no evidence of persistent monoclonal gammopathy detectable by immunoelectrophoresis and immunofixation in serum or urine. Partial haematological response (PR) was defined as 50% loss of serum or urine monoclonal protein in case of still detectable monoclonal plasma cell disease. Serum-free light chain ratio measurements were included into remission assessment according to recently published response criteria. 20 Progression, stabilisation or regression of amyloid deposits were assessed by I 123 -labelled SAP scintigraphy at 12 months post ASCT. Clinical responses were defined for each involved organ system. Response of cardiac, renal, gut or liver disease was defined as described before [11] [12] [13] [14] and according to recently published response criteria. 20 Relapses were defined according to haematological and organ response criteria. 20 
Statistical analysis
The survival of patients post transplant was estimated by Kaplan-Meier analysis and depicted by Kaplan-Meier survival plots. Patient groups were compared using a logrank test. P-values reflected two-sided test results, and those o0.05 were defined as statistically significant. Factors that might influence outcome 9,11-14 were analysed using univariate analyses and included age, organ amyloid load defined by SAP scan at diagnosis, total number of involved organs as defined above, type of predominant organ involvement, initial renal function, chemotherapy prior to HDM-ASCT, time from diagnosis to HDM-ASCT and melphalan dose.
Results
Patient characteristics
Nineteen patients with AL amyloidosis treated by HDM-ASCT at the Hammersmith Hospital, London, between August/1996 and December/2001 were included in the analysis. None of the patients had multiple myeloma with skeletal involvement. Seventeen patients had a monoclonal gammopathy without evidence of multiple myeloma. I 123 -labelled SAP scintigraphy was performed in all patients and showed large amyloid load in three, moderate in six and low in 10 patients. In 17 patients, AL amyloidosis was confirmed histologically by kidney (10), gut (4), liver (1), lung (1), or myocardial (1) biopsy. In two patients with polyneuropathy as the leading organ manifestation, no organ biopsy was performed. Symptomatically predominant kidney involvement was the most common manifestation of amyloidosis in 10 patients. Predominant cardiac involvement was present in three patients. In 12 patients more than two organs were involved. According to risk criteria for ASCT in AL amyloidosis based on the number of organs involved, 11 12 patients were poor and seven were intermediate or good risk candidates. For further details see Tables 1 and 2 . 
Treatment
Before HDM-ASCT, eight patients were treated with cyclic chemotherapy with either vincristine, adriamycin, dexamethasone (VAD) (n ¼ 4), idarubicin, dexamethasone (ZDex) (n ¼ 1), cyclophosphamide, vincristine, adriamycin, prednisone (C-VAMP) (n ¼ 2) or melphalan, prednisone (MP) (n ¼ 1), the other 11 patients proceeded to stem cell mobilisation and transplant without prior therapy. The median time from diagnosis to HDM-ASCT was 16 months (range 2-60 months). Stem cells were mobilised after cyclophosphamide (4 g/m 2 ) and G-CSF in three patients, after etoposide (1.6 g/m 2 ) and G-CSF in one patient and after G-CSF alone in 14 patients. In one patient a bone marrow harvest was performed. A median of 5.2 Â 10 6 CD34 þ cells per kg body weight were collected (range 1.96-50. 17 Â 10 6 ). In the patient who required the bone marrow harvest the cell dose was 4.99 Â 10 8 total nucleated cells per kg body weight. The details of melphalan dose and infused stem cell dose are summarized in Table 2 . Five patients died during the first 100 days post transplant equivalent to a probability of day 100 TRM of 26%. Of those five patients, four were classified as poor risk and one as good risk according to the Comenzo criteria, 11 resulting in a TRM of 33% in the poor risk group and 14% in the intermediate/good risk patients. The causes of death were sepsis in two patients (at days 15 and 19), brain haemorrhage in one patient (day 15) and cardiac arrhythmia in one patient (day 1). The remaining early death was due to multiorgan failure on day 42 despite good peripheral blood count recovery. All 15 patients who survived longer than 28 days from ASCT engrafted and reached neutrophil counts 40.5 Â 10 9 /l and platelet counts 450 Â 10 9 /l at medians of 15 (range 6-25) and 21 days (range 9-32), respectively.
Treatment response
Survival. The median survival from HDM-ASCT was 48 months (range 0-104 months). 73% of patients survived more than 1 year and 62% were alive 2 years after transplant. However, survival by 6 years had fallen to 37% due to disease relapse and/or progression ( Figure 1) . In univariate analyses the involvement of more than two organs and a short disease duration from diagnosis to HDM-ASCT were the only negative predictors for survival (Table 3 ) and the combination of these two factors identified a very poor risk group of patients (Figure 2) . Age, type of predominant organ involvement, SAP scan amyloid load at diagnosis, serum creatinine at time of HDM-ASCT and chemotherapy prior to HDM-ASCT did not impact on survival (Table 3) .
Haematological and clinical response rates. Fourteen patients who survived more than 100 days were evaluable for haematological and clinical responses.
Eight patients (57% of the evaluable 14 and 42% of the original 19 patients) achieved haematological remission at 12 months: five had a complete remission and three a partial remission based on immunoelectrophoresis and/or serum-free light chain ratio. In all eight patients regression of organ amyloid load by SAP scintigraphy and either improvement or stabilisation of organ function were found at 12 months assessment. Disease relapse was diagnosed based on clonal protein and/or serum-free light chain ratio and occurred in five patients after 36, 46, 54, 84 and 110 months from HDM-ASCT. Two patients received a second ASCT for disease relapse. The others were treated with systemic low-dose chemotherapy. All but one patient in this group remain alive at a median follow-up of 80 months (range 42-110 months, see Table 1 ). Six patients (43% of the evaluable 14 and 32% of the original 19) did not show haematological response, displaying stable or progressive plasma cell disease at 12 months assessment. Despite the lack of haematological response, stabilisation of systemic amyloid load in SAP scintigraphy was observed in two and SAP load regression in one patient. As result of progressive renal failure two patients required haemodialysis. Three patients were treated with second and third-line chemotherapy regimens. The median follow-up in this group is 35 months (range 7-83 months, see Table 1 ).
Discussion
Untreated systemic AL amyloidosis is a progressive and fatal disease in almost all cases.
1 High-dose melphalan coupled with autologous stem cell support is used since feasibility was confirmed in early reports, 9,10 but until now opinions on its role in AL amyloidosis are controversial. 8 Procedure-related mortality is high at 14-30%, [11] [12] [13] [14] and symptomatic improvement and recovery of organ function are usually slow. Nevertheless, approximately 50% of patients achieve haematological remission of the plasma cell disease.
11-14 Dispenzieri et al. 16 performed a retrospective matched pair analysis of patients treated with lowdose cyclic melphalan and prednisone chemotherapy and patients treated with HDM-ASCT. They demonstrated a significantly better survival rate for the group of patients treated with high-dose therapy. However, results of the only randomised trial so far performed in 100 patients did not show superior outcome after HDM-ASCT in comparison to M-Dex. 15 A study by Sanchorawala et al.
21
concludes that initial treatment with melphalan and prednisolone does not improve the outcome after HDM, but that treatment delay can have a negative impact on survival.
We report here on HDM-ASCT treatment in a group of 19 patients with AL amyloidosis treated in a single transplant centre. In this group, 74% of patients survived longer than 100 days from transplant and the haematological remission rate was 42% which is comparable with previous findings.
11 -14 Out of 13 patients eligible for SAP scan assessment at 12 months nine patients (47% of initially treated 19) had regression of their amyloid load as shown by the SAP scan. Amyloid regression was observed even in patients who did not achieve complete haematological remission and in some patients without haematological response stable SAP appearance was found. These findings suggest that -contrary to current assumptions -not only stabilisation but even regression of amyloid deposits in several organs is possible if patients achieve haematological response to treatment. We conclude from our findings that high dose chemotherapy with melphalan has the potential to suppress plasma cell proliferation and permit degradation of amyloid deposits in a proportion of patients. A limitation of our study is its retrospective design and the analysis of only one treatment approach. The prospective randomized French study 15 did not prove superiority of HDM-ASCT compared with M-Dex in terms of haematological response, organ function response or survival so that further prospective trials are needed.
High-dose melphalan and autologous stem cell transplantation-related mortality in our patient group was 26%, which is comparable to data reported previously. [11] [12] [13] [14] [21] [22] [23] The proportion of patients with involvement of more than two organs or with poor initial organ function was relatively high at 63%. Indeed, the TRM was particularly high in our poor risk patients (33%), but was appreciably lower in the intermediate and good risk patients (14%). In our group, the only parameters with prognostic impact on survival were extensive organ involvement of more than two organs and time since diagnosis of less than 12 months. Patient age, type of predominant organ involvement, amyloid load estimated by SAP scan, serum creatinine or chemotherapy before transplant did not have an impact on survival. Other authors similarly reported the negative impact of cardiac involvement and involvement of more than two organs. 11, [12] [13] [14] 24 In our patient group the poor survival of patients treated within 12 months from diagnosis probably reflects the selection of poor risk patients as candidates for urgent HDM-ASCT. In contrast, patients who were eligible for ASCT after more than 12 months from diagnosis may have had less aggressive disease biology. Despite previous findings 21 it remains unclear, whether AL amyloidosis patients should be treated with ASCT shortly after diagnosis or after pre-treatment with low-dose chemotherapy. Further prospective studies taking into account different risk groups and comparing HDM-ASCT early in the course of the disease with HDM-ASCT after initial chemotherapy are needed in this field. Unfortunately, poor risk patients with extensive organ involvement are unlikely to do well with conventional therapy and some younger individuals may still elect for transplant. Undoubtedly, better selection of patients most likely to benefit from highdose therapy will result in decreased TRM and improved survival.
Overall survival at 2 years was encouraging at 62% and seven out of eight patients who achieved a haematological response remain alive. On the other hand, we saw late relapses and deaths after 2 years from HDM-ASCT. As the outcome is generally promising for patients surviving the first 100 days from HDM-ASCT, future studies should focus on strategies to prevent and treat disease relapse and progression in patients who do not respond to or relapse after high-dose chemotherapy and ASCT. New strategiesparticularly with the use of proteasome inhibitors or immunomodulatory agents -may prove valuable treatment options for these patients.
